The antibody therapy market is set to thrive at a steady CAGR of 13.4% during the forecast period. The market holds a share of USD 235 billion in 2023 while it is anticipated to cross a value of USD 824.0 billion by 2033.
The research report on the antibody therapy market explains that progressive healthcare efforts, along with the higher government spending on research and development programs, have helped the antibody therapy market expand. Patients suffering from cell-based diseases along with cancer have started opting for the non-chemical, protein-based model that monoclonal antibody therapy provides.
The research and development programs that provide substantial data on higher effectiveness and lower side effects are likely to increase the operability of monoclonal antibody therapy, flourishing the sales of antibody therapies. Furthermore, the expansion of cancer-centric hospitals flourishes the demand for antibody therapy solutions.
The higher FDA approvals of advanced antibody therapy for Covid-19 cases boomed the market growth during the peak of the pandemic. Hence, the market flourished on a much higher CAGR of 18.2% between 2017 and 2022.
The antibody therapy market outlook states that tumor cell resistance to immunotherapy and chemotherapy side effects are also pushing the demand for an alternative. The monoclonal antibodies have become that one alternative with shorter by higher effectiveness.
Thus, the segment becomes the dominant one in the market space. Over the forecast period, the worldwide antibodies market is driven by rising cancer and some other chronic disease prevalence, increasing regulatory approvals and the launch of medicines, and increasing research partnerships for creating a vigorous therapeutic pipeline.
| Attributes | Details |
|---|---|
| Antibody Therapy Market CAGR (2023 to 2033) | 13.4% |
| Antibody Therapy Market Size (2023) | USD 235.0 billion |
| Antibody Therapy Market Size (2033) | USD 824.0 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Short-term Growth: From 2017 to 2022, the global Antibody Therapy market registered a comparatively higher CAGR of 12.1%. The rising prevalence of cancer and its high mortality rate had increased the need for effective and tailored medicines, such as antibody therapy. Antibody-based treatments have evolved technologically by targeting tumor antigens and increasing immune cells' anti-tumor capabilities. Though, the major factor for it experiencing the excessive growth during this period was its experiments against the COVID-19 spread and its usage.
Mid-term Growth: The antibody therapy market is predicted to develop due to rapid product advancement and technologies for cancer treatment. Antibody therapy is a focused, therapeutic intervention that involves using a concentrated or monoclonal antibody to treat diseases such as cancer, infectious disorders, autoimmune diseases, and other The market is likely to grow steadily between 2023 and 2028.
Long-term Growth: Antibodies bind to a specific antigen, which activates or inhibits a series of biological responses, including cancer development inhibition, immune system activation, and many more. During the forecast period, the market for antibody therapy is expected to rise at a steady pace. The Antibody Therapy market is anticipated to thrive at a CAGR of 13.4% between 2023 and 2033.
Owing to the strong demand for antibody therapy, the government and key market companies have greatly expanded research and development spending. As a result, the operation moves to a larger size.
Strong market growth is projected due to government backing for the launch of new treatments. The rising frequency of cancer and other chronic diseases is one of the primary factors driving the global monoclonal antibodies market.
Additionally, increasing regulatory approvals and the debut of new medicines are complementing market growth. The global cancer risk is rapidly increasing, and more secure clinical treatment is being sought over traditional methods.
Monoclonal antibodies may provide advantages, such as recognizing and eliminating a typical cell directly, suppressing cancer cell development, and delivering radioactive particles or chemo medicines to specific cells, reducing the danger of drug side effects while enhancing immune system function.
Principal Consultant
The results of screening and clinical tests are influenced by antibody variation. The development process is a lengthy and challenging task. The technology necessitates huge bioreactors and filtration systems for antibody synthesis, which hinders the worldwide antibody treatment industry.
The market's expansion may be hampered by high costs and tight regulatory requirements that result in a protracted approval process.
Rising governmental spending in cancer research and technology development may open up new potential for the worldwide antibody therapy market to expand.
The healthcare industry is growing at a breakneck speed. The antibody therapy market is experiencing rapid growth due to these advances. On the other hand, more medication market development may be able to help. Antibody treatment alternatives are exploding. In the forecast period, this may have an impact on the overall demand for antibody medication therapy. It can also lead to a plethora of replacements.
The FDA approved Amgen's Repatha (evolocumab) in September 2021 to treat heterozygous familial hypercholesterolemia (HeFH) patients aged 10 and up. Patients suffering from HeFH benefit from this approval. Seagen Inc. and Astellas Pharma Inc. also announced FDA clearance of PADCEV in the United States in September 2021. PADCEV is an ADC-approved medication for urothelial cancer patients with locally progressed or metastatic disease.
Antibody therapy is projected to expand in popularity in the future due to continual product approvals in both developing and established countries. Antibody treatment alternatives are exploding. In the forecast period, this may have an impact on the overall demand for antibody medication therapy. It can also lead to a plethora of replacements.
In addition, the adverse effects of antibody therapy can inhibit growth. Furthermore, genetic treatment is expensive. A combination of replica cells is also used in antibody therapy. It is possible to target and eliminate dangerous cells in the body. This one-of-a-kind procedure is pricey. As a result, the market for antibody therapy is shrinking.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Region | Absolute Market Growth |
|---|---|
| United States | USD 207 billion |
| United Kingdom | USD 23.9 billion |
| China | USD 41.3 billion |
| Japan | USD 32.5 billion |
| South Korea | USD 18.4 billion |
Huge Healthcare Budget along with Rising Number of Cancer Patients in the United States gains traction for the Market
| United States Market CAGR (2023 to 2033) | 13.1% |
|---|---|
| United States Market Absolute Doller Growth (USD Million/Billion) | USD 207.0 billion |
The market is anticipated to continue to be dominated by the United States. Demand for antibody therapy is likely to be high, resulting in high growth. Furthermore, the region's advanced healthcare infrastructure and high healthcare spending are likely to boost the regional market growth.
Due to key players' increased investment in innovative antibody treatment development, the United States antibody therapy market flourished at a higher CAGR of 17.8% during the previous forecast period. As a result of the rising need for targeted medications in the region, clinical studies have increased, contributing to the market's overall growth. Though, the regional market now flourishes at a CAGR of 13.1% between 2023 and 2033, while it is likely to reach a value of USD 291.9 billion by 2033.
Countries like China and India are Building their Advanced Healthcare Systems for the Huge Population
| Region | Attributes |
|---|---|
| Chinese Market CAGR (2023 to 2033) | 12.7% |
| Chinese Market Absolute Doller Growth (USD Million/Billion) | USD 41.3 billion |
China with its leading cell-based science, along with the higher biological experiments, is expected to flourish at a steady CAGR of 12.7% between 2023 and 2033. The regional market is anticipated to reach a value of USD 59.1 billion by 2033. Many patients are drawn to the therapy by low-cost treatments. In addition, the high prevalence of cancer fuels a massive demand for monoclonal antibody therapy. Antibody treatment is in high demand in this area.
The growth of an aging population increases chronic illness rates. This ultimately creates a positive impact on the antibody therapy market.
| Segment | Top Antibody |
|---|---|
| Top Sub-segment | Monoclonal Antibodies |
| CAGR (2017 to 2022) | 18% |
| CAGR (2023 to 2033) | 13.2% |
| Segment | Top End-User |
|---|---|
| Top Sub-segment | Hospitals |
| CAGR (2017 to 2022) | 17.8% |
| CAGR (2023 to 2033) | 12.6% |
Monoclonal antibodies and antibody-drug conjugates are the two antibodies used in antibody therapy. Oncology, autoimmune diseases, infectious illnesses, and other diseases comprise the monoclonal antibodies industry.
Due to the increasing use of monoclonal antibodies (mAbs) to treat different diseases, such as cancer, infection, genetic diseases, and others, the monoclonal antibodies segment is predicted to grow at a 13.2% CAGR through 2023.
As biologic products, mAbs generate various immune-mediated reactions and responses, increasing the therapy's efficacy.
The antibody treatment market is divided into hospitals, specialty centers, and other end-users depending on end-use. The hospital segment thrives at the leading CAGR of 12.6% between 2023 and 2033. Due to guidelines, availability, and accessibility, increasing the number of people seeking treatment in hospitals is expected to boost the market growth. Other factors for this segment’s growth are advanced therapy, quick access to advanced care, post-treatment monitoring, presence of competent personnel all in one location
The fresh entry of significant players, on the other hand, may enhance competition. In addition, significant strategies in the competitive environment include expansion, acquisitions, partnerships, mergers, and acquisitions. In the approaching years, this market invests heavily in research and development to strengthen its position in the antibody industry and help them expand into big players.
Recent Market Developments
The global market size is estimated to be USD 235 billion in 2023.
The overall market has the potential to grow at 13.4% CAGR through 2033.
The market expanded at 12.1% CAGR from 2017 to 2022.
The country to follow an impressive 13.1% CAGR through 2033.
The sales of monoclonal antibodies surged at 18% from 2017 to 2022.
1. Executive Summary | Antibody Therapy Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Type 5.1. Monoclonal Antibodies 5.1.1. Oncology, Autoimmune Disease 5.1.2. Infectious Disease 5.1.3. Other 5.2. Antibody Drug Conjugates 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospitals 6.2. Specialty Centers 6.3. Others 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa 8. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. F. Hoffmann-La Roche Ltd 15.2. AbbVie Inc 15.3. Amgen Inc 15.4. Bristol-Myers Squibb Company 15.5. Johnson & Johnson Services, Inc 15.6. Seagen 15.7. Merck & Co. Inc 15.8. Regeneron Pharmaceuticals Inc 15.9. Novartis AG 15.10. AstraZeneca 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Antibody Therapy Market
